Abstract Diabetic Kidney Disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide
Safety Monitoring Recommendations Based on the available clinical trial data, clinicians prescribing orforglipron should: (1) counsel patients about expected GI side effects during dose escalation, (2) follow the recommended dose-titration schedule to minimize GI intolerance, (3) monitor for signs of pancreatitis and discontinue if suspected, (4) assess hepatic and renal function at baseline and periodically, (5) screen for personal or family history of MTC or MEN 2, and (6) review concomitant medications for potential CYP3A-mediated drug interactions
The boom in compounded semaglutide when brand prices were higher and Eli Lillys push to offer Zepbound vials through lower priced self-pay channels both point in the same direction: when GLP-1 prices fall in cash-pay settings, demand responds quickly
Misconception: if you have any thyroid problem you cannot take tirzepatide This is perhaps the most damaging misconception
Lancet Diabetes Endocrinol 8(12):960970 Kamermans A, Verhoeven T, van Het Hof B, Koning JJ, Borghuis L, Witte M et al (2019) Setmelanotide, a novel, selective melanocortin receptor-4 agonist exerts anti-inflammatory actions in astrocytes and promotes an anti-inflammatory macrophage phenotype
The environment is sterile (thanks to the doctors), so infection isn't the primary worrydeep tissue regeneration is
